Evolus, Inc. (0K16.L)
USD 11.39
(0.03%)
USD 11.39
(0.03%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -61.68 Million USD | 17.1% |
| 2022 | -74.41 Million USD | -58.97% |
| 2021 | -46.81 Million USD | 71.28% |
| 2020 | -163.01 Million USD | -81.06% |
| 2019 | -90.03 Million USD | -92.11% |
| 2018 | -46.86 Million USD | -946.14% |
| 2017 | -4.48 Million USD | 77.67% |
| 2016 | -20.06 Million USD | 35.51% |
| 2015 | -31.11 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -13.1 Million USD | -10.8% |
| 2024 Q2 | -11.35 Million USD | 13.42% |
| 2023 FY | -61.68 Million USD | 17.1% |
| 2023 Q2 | -18.14 Million USD | -22.64% |
| 2023 Q1 | -14.79 Million USD | -12.36% |
| 2023 Q3 | -16.92 Million USD | 6.71% |
| 2023 Q4 | -11.83 Million USD | 30.09% |
| 2022 Q2 | -23.47 Million USD | -34.11% |
| 2022 Q4 | -13.16 Million USD | 35.08% |
| 2022 Q3 | -20.27 Million USD | 13.61% |
| 2022 FY | -74.41 Million USD | -58.97% |
| 2022 Q1 | -17.5 Million USD | 3.72% |
| 2021 Q1 | 6.4 Million USD | 105.78% |
| 2021 Q2 | -15.6 Million USD | -343.73% |
| 2021 Q3 | -19.43 Million USD | -24.56% |
| 2021 Q4 | -18.17 Million USD | 6.46% |
| 2021 FY | -46.81 Million USD | 71.28% |
| 2020 Q2 | -21.12 Million USD | -7.04% |
| 2020 FY | -163.01 Million USD | -81.06% |
| 2020 Q3 | -11.45 Million USD | 45.76% |
| 2020 Q4 | -110.69 Million USD | -866.0% |
| 2020 Q1 | -19.73 Million USD | -36.03% |
| 2019 Q3 | -26.98 Million USD | 28.17% |
| 2019 FY | -90.03 Million USD | -92.11% |
| 2019 Q4 | -14.5 Million USD | 46.23% |
| 2019 Q2 | -37.56 Million USD | -242.3% |
| 2019 Q1 | -10.97 Million USD | 11.79% |
| 2018 Q2 | -16.43 Million USD | -166.68% |
| 2018 FY | -46.86 Million USD | -946.14% |
| 2018 Q4 | -12.44 Million USD | -5.17% |
| 2018 Q3 | -11.83 Million USD | 28.01% |
| 2018 Q1 | -6.16 Million USD | -238.53% |
| 2017 Q2 | -2.29 Million USD | 42.57% |
| 2017 Q3 | -2.63 Million USD | -14.72% |
| 2017 Q1 | -3.99 Million USD | -6.81% |
| 2017 FY | -4.48 Million USD | 77.67% |
| 2017 Q4 | 4.44 Million USD | 268.87% |
| 2016 Q4 | -3.74 Million USD | 10.02% |
| 2016 Q2 | -6.08 Million USD | 0.0% |
| 2016 Q3 | -4.16 Million USD | 31.59% |
| 2016 Q1 | -6.08 Million USD | 0.0% |
| 2016 FY | -20.06 Million USD | 35.51% |
| 2015 FY | -31.11 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Editas Medicine, Inc. | -153.21 Million USD | 59.741% |
| Dynavax Technologies Corporation | -6.38 Million USD | -865.488% |
| Supernus Pharmaceuticals, Inc. | 1.31 Million USD | 4787.31% |
| Perrigo Company plc | -12.7 Million USD | -385.709% |
| Illumina, Inc. | -1.16 Billion USD | 94.687% |
| Thermo Fisher Scientific Inc. | 5.99 Billion USD | 101.029% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 86.108% |
| Walgreens Boots Alliance, Inc. | -8.63 Billion USD | 99.286% |
| IQVIA Holdings Inc. | 1.35 Billion USD | 104.542% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 44.206% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 101.56% |
| Unity Biotechnology, Inc. | -39.86 Million USD | -54.754% |
| Waters Corporation | 642.23 Million USD | 109.605% |
| Biogen Inc. | 1.16 Billion USD | 105.313% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 76.075% |
| Adicet Bio, Inc. | -142.65 Million USD | 56.76% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 47.951% |
| bluebird bio, Inc. | -211.91 Million USD | 70.891% |
| Esperion Therapeutics, Inc. | -209.24 Million USD | 70.521% |
| FibroGen, Inc. | -284.23 Million USD | 78.298% |
| Agilent Technologies, Inc. | 1.24 Billion USD | 104.975% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | -38.297% |
| Homology Medicines, Inc. | -53.74 Million USD | -14.778% |
| Geron Corporation | -184.12 Million USD | 66.499% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 85.988% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 59.306% |
| Myriad Genetics, Inc. | -112 Million USD | 44.924% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 28.186% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 87.181% |
| Zoetis Inc. | 2.34 Billion USD | 102.632% |
| Abeona Therapeutics Inc. | -54.18 Million USD | -13.835% |
| Mettler-Toledo International Inc. | 788.77 Million USD | 107.82% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 136.795% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 101.704% |
| Kala Pharmaceuticals, Inc. | -42.19 Million USD | -46.176% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 83.159% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 77.661% |
| Verastem, Inc. | -87.36 Million USD | 29.396% |
| Nektar Therapeutics | -276.05 Million USD | 77.655% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 74.216% |
| Aclaris Therapeutics, Inc. | -88.48 Million USD | 30.284% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 88.491% |
| OPKO Health, Inc. | -188.86 Million USD | 67.339% |
| Exelixis, Inc. | 207.76 Million USD | 129.69% |
| Neurocrine Biosciences, Inc. | 249.7 Million USD | 124.704% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 158.117% |
| Anavex Life Sciences Corp. | -47.5 Million USD | -29.849% |
| uniQure N.V. | -308.47 Million USD | 80.003% |
| Imunon, Inc. | -19.51 Million USD | -216.091% |
| Blueprint Medicines Corporation | -506.98 Million USD | 87.833% |
| Insmed Incorporated | -749.56 Million USD | 91.771% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 121.906% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 82.48% |
| TG Therapeutics, Inc. | 12.67 Million USD | 586.782% |
| Incyte Corporation | 597.59 Million USD | 110.322% |
| Emergent BioSolutions Inc. | -760.5 Million USD | 91.889% |